

#### Characteristics of the ToxCast In Vitro Datasets from Biochemical and Cellular Assays

Keith Houck TDAS May 14-15, 2009

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

This work was reviewed by EPA and approved for presentation but does not necessarily reflect official Agency policy. Mention of trade names or commercial products does not constitute endorsement or recommendation by EPA for use.

COMPUTATIONA

Office of Research and Development National Center for Computational Toxicology



## **Outline: ToxCast Data Sets Overview**

- Data Sets: Bio-centric View
  - -Assay overview
  - -How were the data calculated?
  - -How did the replicates perform?
  - -Example results
  - -What did the assay measure?
  - -Potential assay artifacts



## **ToxCast Phase I Data Sets**

- Biochemical
  - -Novascreen

- Cell-Based
  - -ACEA
  - -Attagene
  - -BioSeek
  - -Cellumen
  - -CellzDirect
  - -Gentronix
  - -NCGC
  - -Solidus



#### Novascreen: 239 Biochemical Assays (Abstract 59)

- Protein super-families
  - GPCR
  - -Kinase
  - Phosphatase
  - Protease
  - Ion channel
  - Nuclear receptor
  - Other enzyme
  - -CYP P450 inhibition

- Various formats:
  - Radioligand receptor binding
  - Fluorescent receptor binding
  - Fluorescent enzyme substrateintensity quench
  - Fluorescent enzyme substratemobility shift
- Initial screening:
  - $-25 \ \mu M$  in duplicate
  - $-10 \ \mu M$  in duplicate (CYPs)
- Normalize data to assay window
  - % of control activity (central reference scalar reference)



## Novascreen: What do the assays measure?

- Mainly direct effects of chemical on target protein
  - Enzyme activity
  - Ligand binding
- False positives:
  - Fluorescent compounds-fluorescing and quenching
  - Reactive compounds/covalent modification of target
  - Physical effects—colloid aggregation of target
  - Operational
- False negatives:
  - Solubility
  - Inappropriate enzymatic conditions
  - Operational
  - Target protein not physiological
  - Lack of biotransformation

#### **Data Correction Algorithm Examples (Additive)**

#### AChE

	AChE									Caspase 10																
		1	2	3	4	5	6	7	8	9	10	11	12		1	2	3	4	5	6	7	8	9	10	11	12
	A	-3	3	-29	-100	-98	-100	-68	-68	-89	-89	-98	-98	А	25	0	-3	-97	-100	-101	-35	-33	-76	-80	-100	-99
	В	-4	7	-29	-12	-10	-12	-27	-22	-30	-30	-25	-16	В	9	-17	-16	-23	-28	-17	-13	-16	-22	-15	-22	-3
	С	8	2	-23	-23	-19	-26	-25	-26	-26	-28	-25	-13	С	3	-22	-10	-27	-24	-20	-39	-31	-24	-28	-26	-6
normalized	D	-14	1	-17	-21	-23	-25	-18	-26	-26	-27	-25	-17	D	15	-22	-15	-27	-23	-27	-13	-15	-17	-18	-20	-3
normanzoa	Е	-11	-5	-23	-25	-16	-20	-26	-22	-27	-30	-26	-13	Ε	3	-16	-16	-17	-18	-7	-6	-13	2	5	-17	12
	F	-16	0	-7	-7	-17	-21	-22	-24	-29	-33	-19	-17	F	-11	-34	-18	-26	-29	-21	-22	-19	-18	-19	-25	0
	G	-5	4	-32	-18	-25	-17	-25	-28	-25	-32	-20	-13	G	-23	-30	-27	-24	-17	-6	-8	-11	-22	-12	-9	10
	н	-85	-78	-22	-22	2	-14	-17	-17	NaN	NaN	NaN	NaN	Н	-15	-28	-17	-20	-14	-28	-5	4	-19	-4	-18	5
		1	2	3	4	5	6	7	8	9	10	11	12		1	2	3	4	5	6	7	8	9	10	11	12
	A	-1	1	-19	-100	-98	-100	-67	-67	-89	-89	-98	-98	А	23	0	-3	-97	-100	-101	-36	-34	-76	-81	-100	-99
	В	0	7	-20	-10	-2	0	2	9	-15	-16	-9	-4	В	13	6	7	0	-6	-3	3	2	-6	1	-5	0
Normalized	С	10	10	-3	-3	0	-6	-2	-5	-16	-18	-11	-1	С	6	-1	10	-7	-4	-5	-21	-13	-5	-10	-7	-5
& corrected	D	4	14	7	2	2	-5	6	0	-13	-11	-9	-3	D	18	0	2	-7	0	-7	6	4	0	-1	-4	1
	Ε	7	13	4	0	7	4	-2	2	-15	-18	-10	-1	Ε	1	1	2	-3	-5	-2	7	0	14	17	-6	9
	F	5	22	16	16	9	6	3	3	-15	-17	-3	-2	F	-9	-12	4	-3	-11	-9	-4	-1	-7	-4	-11	-1
	G	12	23	-4	6	1	5	3	0	-11	-16	-1	4	G	-17	-5	-5	-4	-1	-1	13	6	-2	3	5	8
	Н	-52	-44	7	9	20	8	4	5	NaN	NaN	NaN	NaN	Н	-9	-11	2	0	4	-14	9	15	-4	10	-7	8
Office of	<b>D</b>																									

**Office of Research and Development** National Center for Computational Toxicology

#### **Novascreen Concentration-Response**




#### Retest actives:

 Median absolute deviation (MAD) median | x-xmed | two MADs or 30% activity


Testing

- -8 conc/3-fold serial dilutions
  - + 50  $\mu M$  high conc
  - + 25  $\mu$ M high conc for CYPs
- Normalize to assay window
- Fit % Activity data to 3- or 4parameter Hill function
  - Sometimes had to fix top or bottom of curve
  - Did not extrapolate beyond testing range
  - Manual or automated removal of obvious outliers




6


#### **Novascreen: Example Curve Fits**




United States




TV000526:Paclobutrazol



TV000551:Amitraz



TV000541:Cyproconazole




VUUU/83:Mancozeb

#### **ACEA: Real Time Cell Growth Kinetics**



- Cytotoxicity with potential mechanistic interpretation
- Human A549 lung carcinoma cell line
  - -ACEA experience with line
  - -Reference compound effects
- Concentration-response testing
  - -8 conc/3-fold serial dilutions
  - -Duplicate wells
- Real-time measurements during exposure (0-72 hr)
- IC50 and LECs calculated





### ACEA: What is measured?


- General cytotoxicity in transformed cell line
- False positives
  - -None obvious
  - -Operational
- False negatives
  - -Operational error
  - -Solubility
  - -Lack of appropriate toxicity targets (irrelevant cell line)
  - -Lack of biotransformation



#### **ACEA: Data Examples**

ACEA


0





#### Attagene Multiplexed Transcription Reporter Assays

- Modulation of TF activity in human hepatoma HepG2 cells
- Multiplexed reporter gene assay
  - -*cis* 52 assays (response element driving reporter)
  - -trans 29 assays (GAL4-NR\_LBD driving reporter) "ligand detection"
- IC50 for cytotoxicity measured first in HepG2
- High concentration either 100  $\mu M$  or 1/3 calculated IC50 for cytotoxicity
- Seven concentrations, 3-fold serial dilutions, 24 hr exposure
- Cells harvested, RNA isolated, processed for reporter gene quantitation
- LEC provided in data set





#### **Attagene: What Is Being Measured?**

- cis Assays
  - Up/down regulation of endogenous transcription factor activity in transformed cell line
  - False positives
    - General cytotoxic response resulting in non-specific transcriptional activity
    - Promiscuity of response elements
    - Statistical, not biologically, significant response
    - Operational
  - False negatives
    - Solubility
    - Cytotoxicity
    - Operational
    - Lack of endogenous machinery
    - Lack of biotransformation

- trans Assays
  - NR agonist activity
  - False positives
    - General cytotoxic response resulting in non-specific transcriptional activity
    - Statistical, not biologically, significant response
    - Operational
  - False negatives
    - Solubility
    - Cytotoxicity
    - Operational
    - Lack of endogenous machinery
    - Lack of biotransformation




#### Attagene: Corresponding cis and trans Assays

HPTE

**Bisphenol A** 





cis: ERE

#### **Attagene: Data Calculation Challenges**

 No positive reference compound for each endpoint

United States


Agency

**Environmental Protection** 

cis: HIF1a

log Concentration [M]

- Responses, especially for *cis* assays, tended to be monotonic so potency value difficult to derive
- Biological vs statistical significance for LEC



Attagene Replicate Analysis

3-

25

1

Activities [%]

ploc

1.8

1.6

1.4

1.2

1-

4

log Concentration [M]

Activities [%]

log Concentration [M]




#### **BioSeek: BioMAP® Technology Platform (Abstract 24)**


Assays

#### **Profile Database**

#### **Informatics**







Human primary cells Disease-like culture conditions

## Biological responses to drugs and stored in the database

Specialized informatics tools are used to mine and analyze biological data

Primary Human Cell-Based Assay Platform for Human Pharmacology

Office of Research and Development National Center for Computational Toxicology

## SEPA BioSeek Assays Tested Against ToxCast\_320


System		Cell Types	Environment	Readouts					
3C	8	Endothelial cells	IL-1β+TNF-α+IFN-γ	MCP-1, VCAM-1, ICAM-1, Thrombomodulin, Tissue Factor, E-selectin, uPAR, IL-8, MIG, HLA-DR, Prolif., Vis., SRB (13)					
4H	8	Endothelial cells	L-4+histamine	VEGFRII, P-selectin, VCAM-1, uPAR, Eotaxin-3, MCP-1, SRB (7)					
LPS	<b>9</b> 39	Peripheral Blood Mononuclear Cells + Endothelial cells	TLR4	CD40, VCAM-1, Tissue Factor, MCP-1, E-selectin, IL-1a, IL-8, M-CSF, TNF-a, PGE2, SRB (11)					
SAg		Peripheral Blood Mononuclear Cells + Endothelial cells	TCR	MCP-1, CD38, CD40, CD69, E-selectin, IL-8, MIG, PBMC Cytotox., SRB, Proliferation (10)					
BE3C	888	Bronchial epithelial cells	IL-1β+TNF-α+IFN-γ	uPAR, IP-10, MIG, HLA-DR, IL-1a, MMP-1, PAI-1, SRB, TGF-b1, tPA, uPA (11)					
HDF3CGF	-	Fibroblasts	IL-1β+TNF-α+IFN-γ +bFGF+EGF+PDGF-BB	VCAM-1, IP-10, IL-8, MIG, Collagen III, M-CSF, MMP-1, PAI-1, Proliferation, TIMP-1, EGFR, SRB (12)					
KF3CT		Keratinocytes + Fibroblasts	IL-1β+TNF-α+IFN-γ +TGF-β	MCP-1, ICAM-1, IP-10, IL-1a, MMP-9, TGF-b1, TIMP-2, uPA, SRB (9)					
SM3C	-	Vascular smooth muscle cells	IL-1β+TNF-α+IFN-γ	MCP-1, VCAM-1, Thrombomodulin, Tissue Factor, IL-6, LDLR, SAA, uPAR, IL-8, MIG, HLA-DR, M-CSF, Prolif., SRB (14)					



#### **BioSeek Assays**

- Chemicals tested at 4 concentrations: 40, 13.3, 4.4, 1.5  $\mu M,$  single well
- Exposure started 1 hr before stimulation of cell signaling pathways
- Following 24 hr exposure, endpoints measured by ELISA (also Alamar blue, SRB staining, and microscopy)
- Data calculated vs 6 DMSO controls as fold-change
- Up and down regulation distinguished
- LECs determined








#### **BioSeek Assays: What is Being** Measured?

- Effects of chemicals on signaling pathways in primary human cells
- False positives
  - -Cytotoxicity (down-regulation in particular)
  - -Statistical vs biological significance
  - -Operational
- False negatives
  - -Solubility
  - -Lack of biotransformation
  - -Cytotoxicity
  - -Operational



#### **BioSeek MOA Signatures** Defined by reference cmpd behavior in assays used




20



#### Cellumen: High-Content Screening of Cellular Phenotypic Toxicity Parameters (Abstract 38)

- Technology: automated fluorescent microscopy
- Objective: Determine effects of chemicals on toxicity biomarkers in a cell culture of HepG2 and primary rat hepatocytes





## Cellumen: CellCiphr™ Cytotoxicity Panel

- 10-point conc-response (200  $\mu$ M-39 nM) in duplicate
- Three time points (1 hr, 24 hr, 72 hr)
- 11 endpoints per assay

Biomarker	Measurement	Positive Control	Z'
Stress Pathway	Phospho-c-jun	Anisomycin	0.63
Oxidative Stress	Phospho-Histone H2A.X	Camptothecin	0.7
Mitochondrial Function	Mitochondrial membrane potential	CCCP	0.55
Mitochondrial Mass	Mitochondrial mass	CCCP	0.35
Cell Loss	Cell number	Camptothecin	0.56
Cell Cycle	DNA content	Paclitaxel	0.54
DNA Degradation	DNA structure	Paclitaxel	0.6
Nuclear Size	Area of nuclear region	Paclitaxel	0.63
DNA Damage	Detection of p53	Camptothecin	0.43
Mitotic Arrest	Phospho-Histone-H3	Paclitaxel	0.63
Cytoskeletal Integrity	Detection of -tubulin	Paclitaxel	0.3




## **Cellumen: What is Being Measured?**

- Cellular toxicity phenotypes in a transformed cell line
- False positives
  - -Imaging artifacts
  - -Fluorescent compounds
  - -Statistical vs biological significance
  - -Operational
- False negatives
  - -Solubility
  - -Cytotoxicity
  - -Lack of biotransformation
  - -Operational




#### **Cellumen: Data Calculation**

- Data not normalized to controls (with a few exceptions)
- Fit to 3- or 4-parameter Hill equation
- AC50 reported with these rules:
  - For Cell Loss, AC50 is reported as calculated
  - For other endpoints, if AC50 for endpoint is > AC50 for Cell Loss at the corresponding exposure time, AC50 for endpoint is set to 100  $\mu$ M (to account for imaging artifacts of cytotoxicity
- Issues:
  - Lack of positive controls for all endpoint/time combinations
  - Large differences in maximal response
  - noisy curves due in part to effects of cytotoxicity



Cellumen


#### **Cellumen: Data Examples**





#### CellzDirect: XME Gene Expression in Primary Human Hepatocytes (Abstract 22)

- Primary human hepatocytes from two donors used
- Cells exposed for 6, 24, and 48 hr; medium/chemical refreshed daily
- Concentrations tested: 40, 4, 0.4, 0.04, and 0.004 µM
- 16 Genes measured in multiplexed RNAse protection assay (qNPA)
- Genes targeted XME and transporters



CYP3A4

CYP2C19

SLCO1B1

ACTIN




- Normalized to solvent control; expressed as fold-change
- Curves fit to Hill equation
  - Upper and lower limits defined by minimum and maximum responses observed over dataset of a particular gene/donor/time
- LECs determined

Environmental Protection

Agency

- Large variations in maximal responses

   Biological vs statistical significance
- Measuring endogenous promoter activity reflects complex, multifactorial regulation of gene expression
- 6 hr exposure data not provided due to high variability associated with limited time for gene induction



CellzDirect

#### **CellzDirect: Data Examples**

CYP1A1-AhR HMGCS2-PPAR  $\alpha$ CYP2B6-CAR CYP1A1 (6hr) - EC50: 0.2002 -33 HMGCS2 (6hr) - EC50: 14.22 CYP2B6 (6hr) - EC50: 0.08564 -8-CYP1A2 (6hr) - EC50: 0.1746 . HMGCS2 (24hr) - EC50: 4.115 CYP2B6 (24hr) - EC50: 0.05418 . 2500 CYP1A1 (24hr) - EC50: 0.8615 HMGCS2 (48hr) – EC50: 8.509 CYP2B6 (48hr) - EC50: 0.04235 5 CYP1A2 (24hr) - EC50: 0.3658 CYP1A1 (48hr) - EC50: 0.6212 25 CYP1A2 (48hr) – EC50: 0.1125 • 2000 ŧ Fold Induction / Control Fold Induction / Control Fold Induction / Control 20 ₫ 1500 9 15 1000 4 ₽ 5 500 ŝ 0.005 0.020 0.050 0.200 0.500 2.000 0.002 0.005 0.020 0.050 0.200 0.500 1.0 10.0 20.0 50.0 200.0 0.5 2.0 5.0 Log Concentration (µM) Log Concentration (µM) Log Concentration (µM) Dotor TTe
 Dotor TTe Boner 776 Denor 776 Phyperampons (2000 = 1,157 att 1 %, Chicasy Solarts Bander (2000 = 4,423 will 1 %, Chicasy 31,875 Traditionate (2000 = 1739-44) %, Solarey 31,875 Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 1,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (2000 = 3,374 will 1 %, Efficient (31,28) Coumepting (31,28) C Donor 776 \$ Donor 776 Lacather ECSD = 1 MS all ( N. Effaang 131/2%) Demokformentigt ECRD = 0 ST4 all 1 N. Effaang 55/55% Pyctholour-tactium ECSB = 1.75 all ( N. Effaang 52/35%) . Data 110 Destantaria 2001 - 2.011 M () & Disary 81.01% Destantaria 2001 - 4.011 M () & Disary 81.01% Overagene 2000 - 1.501 M () & Disary 10.11% Plotate 6000 - 1.511 M () & Disary 10.01% Disary 6000 - 2.011 M () & Disary 10.01% Disary 6000 - 2.011 M () & Disary 10.01% Characteristics 2000 - 404 A M () & Disary 10.00% Characteristics 2000 - 404 A M () & Disary 10.00% \*\*\* ...... -----2 Vetossceli ECRU = 0.014 eM 1 % Efficant 55.19%
 Peroferic Aut ECRU = 5.09 eM 1 % Efficant 10.0%
 Fenditric Aut ECRU = 3.805 eM 1 % Efficant 10.0% Benaultele ECR0 = 0.744 vM 2 % Elfosoy 48.17% Tetruprientes ECR0 = 5.448 vM 3 % Elfosoy 38.41% \* Ritempton EC66 = 6.138 uM 3. % Efforce 180.0%
 Ritempton EC58 = 8.5 uM 1. % Efforce 180.0% 8 2 102 80 唐 5 484 10 10 8 8 콤 3 £ 1 10 10 10 54-81 50-02 5+-01 54+95 54481 14-31 14+08 10+01 1++62 10-00 14-82 10-90 14402 Log Concentration (µW) Log Concentration (µM) Log Concentration (µM)




## **CellzDirect: What is Being Measured?**

- Up/down regulation of mRNA for XME and transporters in primary human hepatocytes
- False positives:
  - -General effect of cytotoxicity on transcriptional activity
  - -Statistical vs biological significance
  - -Operational
- False negatives:
  - -Solubility
  - -Cytotoxicity
  - -Operational
  - -Lack of biotransformation
  - -Inter-individual donor variation



#### Gentronix: GADD45a Reporter Gene Assay for DNA Damage (Abstract 41)

- TK6 cell line expressing GFP under control of GADD45a promoter
- $\bullet$  Cells exposed at 200, 100, 50  $\mu M$  for 24 and 48 hr
- Cytotox assay to discount artifacts
- Retested at lower conc if cytotoxic





#### **Gentronix: Data Calculations**


- Induction of GFP fluorescence
   >50% = genotoxic
- If over 2 or 3 concentrations, strongly genotoxic
- LELs calculated
- Replicate analysis: no actives among replicates

- False positives:
  - Cytotoxicity resulting in general transcriptional activity
  - Cellular stress other than DNA damage
  - Statistical vs biological validation
  - Operational
- False negatives:
  - Solubility
  - Cytotoxicity
  - Lack of biotransformation
  - Operational



### Solidus: Biotransformation Chip and Effect of Cytotoxicity (Abstract 30)

- Alginate-immobilized Phase I and Phase II enzymes
- ToxCast\_320 exposed 6 hr to:
  - Control
  - Ph I
  - –Ph II
  - Ph I and Ph II
- 960 µM high conc/4-fold serial dilutions/9 concentrations/5 replicates
- Cytotoxicity in Hep3B measured 48 hr later



#### Solidus




150·


 Data normalized to control values


Agency

150

- Concentration-response data fit to Hill equation
- LC50 determined for each assay condition









### **Solidus: What is Being Measured?**

- Effect of Phase I and Phase II enzymes on cytotoxicity activity of chemicals against a transformed cell line
- False positives:
  - -Possibly not optimized Phase I and/or Phase II mix
  - -Operational
- False negatives
  - -Solubility
  - -Possibly not optimized Phase I and/or Phase II mix
  - Availability of compound from alginate-immobilized enzyme matrix
  - -Operational




#### **NCGC Reporter Gene Assays**

- Nuclear Receptors
  - -GAL4 System (ligand detection assay)
  - -11 human receptors
  - -1 rat (PXR)
  - $-\beta$ -lactamase reporter gene assays except:
  - PXR assays are luciferase reporter gene assays
- p53 Reporter Gene assay
  - $-\beta$ -lactamase reporter gene assay
- Parental cell lines mostly HEK293 (also HeLa and DPX-2)
- 12-15 point concentration-response curves (single replicate)

## NCGC: Data Calculations

- Data normalized to reference compound effect
- Curves fit to 3- or 4-parameter Hill equation
- Artifacts removed where obvious fluorescence or cytotoxicity detected
- Required at least 25% efficacy of control compound to calculate AC50
- AC50 values provided
- Antagonist format assays challenging due to effects of cytotoxicity
- LXR assay problematic contaminated with GR reporter line?



NCGC00022570-07



# NCGC Assays: What is Being Measured?

- NR assays are ligand-detection assays
- False positives
  - -Fluorescent compounds
  - Statistical vs biological significance
  - Gal4\_NR-LBD not physiological
  - Cytotoxicity (antagonist format)
  - Operational
- False negatives
  - Fluorescent compounds
  - Cytotoxicity
  - Gal4\_NR-LBD not physiological
  - Operational
  - Lack of biotransformation



#### Additional Data Sets To Be Added Soon:

- NHEERL
  - -Zebrafish developmental toxicity (Padilla) Poster
  - -Neurite outgrowth and neuronal proliferation (Mundy and Shafer)
  - -Stress gene reporter assays (Simmons)
  - -ES cell differentiation (Hunter)
- Plasma protein binding and hepatocyte clearance (Thomas)
- PPAR $\alpha$  and AhR (NCGC)
- Primary rat hepatocyte HCS Cell Health (Cellumen)